**South African National Essential Medicine List**

**Primary Healthcare/ Adult Hospital Level of CareMedication Review Process**

**Component: Emergencies and injuries**

**MEDICINE REVIEW**

1. **Executive Summary**

|  |
| --- |
| **Date:** 18 August 2022**Medicine (INN):** Olanzapine (IM, orodispersible)**Medicine (ATC):** N05AH03**Indication (ICD10 code):** Delirium F05.0/.1/.8/.9**Patient population:** Adults with delirium who are agitated or considered a risk to themselves or others, and non-pharmacological measures are ineffective.**Prevalence of condition:** South African studies* 12.3% of acute medical inpatients ([Du Plooy, 2020](http://www.samj.org.za/index.php/samj/article/view/12966))1
* 17.6% of acutely admitted people with HIV ([Day, 2021](http://www.samj.org.za/index.php/samj/article/view/13401))2

International studies* Approximately 20% of general adult inpatients and 80% of mechanically ventilated patients in ICU ([Nikooie, 2019](https://www.acpjournals.org/doi/10.7326/M19-1860))3

**Level of Care:** Primary Healthcare**Prescriber Level:** Doctor prescribed**Motivator/reviewer name(s):** Lesley Robertson, Shelley McGee, Tamara Kredo, Natasha Gloeck, Mashudu Mthethwa, Trudy Leong**PTC affiliation:** Lesley Robertson affiliated to Sedibeng District PTC, Gauteng |

**Key findings**

|  |
| --- |
| * Haloperidol IM is current standard of care in the management of delirium non-responsive to non-pharmacological measures. However, 5mg/ml and 20mg/2ml injections are no longer available on the South African market.
* Olanzapine is available in South Africa as oro-dispersible tablets and IM formulations and is a possible alternative.
* We conducted a review of available evidence to determine the efficacy and safety of olanzapine in the management of delirium.
* Three clinical practice guidelines were identified. Two of the guidelines (both with AGREE II scores of 83%) included olanzapine as an alternative to haloperidol. The third guideline (AGREE II 67%) noted a need for more evidence to enable a recommendation regarding antipsychotic use in delirium.
* A search of PubMed, the Cochrane Library, and Epistemonikos identified two systematic reviews (three relevant RCTs) and two additional RCTs. Study settings included palliative care, a medical emergency ward, and critical care. Oral and IM formulations of olanzapine and haloperidol were used.
* Compared to placebo, from one RCT suggests that olanzapine showed superiority in a) duration of delirium (MD=-2.4 days, 95% CI -3.51 to -1.29), and b) delirium severity, as measured by the delirium rating scale (MD = -11.1, 95% CI -15.51 to -7.69).
* Compared to haloperidol, very low certainty evidence suggests little to no difference in duration of delirium with a MD of 0.62 days, 95% CI 0.06 to 1.18 in one RCT and a difference of 3.57 days (+- 0.92 days) for olanzapine vs 3.37 days (+- 0.71 days) for haloperidol in another RCT. No difference was found in delirium severity scores among terminally ill patients (MD = 2.36 (95% CI -0.75 to 5.47) at 24 hours and MD =1.90 (95% CI -1.50 to 5.30) between 24 to 48 hours), very low certainty evidence, and in a medical emergency ward (MD = 0.7, 95% CI 0.45 to 1.85), uncertain evidence.
* No reviews nor trials were identified comparing olanzapine to benzodiazepines in the treatment of delirium.
* No serious adverse events were documented for either olanzapine or haloperidol.
* In conclusion, olanzapine may be superior to placebo and comparable to haloperidol in the management of delirium. Oral formulations of either haloperidol or olanzapine may be used in patients able to swallow.
 |

|  |
| --- |
| **PHC/ADULT HOSPITAL LEVEL EXPERT REVIEW COMMITEE RECOMMENDATION:**  |
| **Type of recommendation** | We recommend against the option and for the alternative**(strong)** | We suggest not to use the option **(conditional)** | We suggest using either the option or the alternative **(conditional)** | We suggestusing the option **(conditional)** | We recommendthe option**(strong)** |
|  |  |  | **X** |  |
| **Recommendation:** The PHC/ Adult Hospital Level Committee suggests using olanzapine (oral, orodispersible and parenteral formulations) as an option to manage delirium where non-pharmacological management is not sufficient.*Rationale:* Available low-quality evidence shows that haloperidol is comparable to olanzapine**Level of Evidence: Low to very low certainty evidence** **Review indicator:** Evidence of harm, efficacy |
| **NEMLC RECOMMENDATION (20 OCTOBER 2022 MEETING):**The NEMLC considered the recommendation, as proposed by the PHC/Adult Hospital Level Committee and concerns were raised regarding the feasibility of administering medication via NGT to a patient with delirium. Alternative agents were also discussed, noting the reported paucity of evidence for clotiapine and the safety concerns of droperidol (QT-prolongation). NEMLC recommended olanzapine oro-dispersible tablet or IM for delirium with agitated and acutely disturbed behaviour. Once the patient is able to swallow, to continue with oral haloperidol or olanzapine, until behaviour is contained. |
| [**Monitoring and evaluation**](#Monitoring) **considerations** |
| **Research priorities** |

1. **Name of author(s)/motivator(s)**

Lesley Robertson, Tamara Kredo, Mashudu Mthethwa, Natasha Gloeck, Shelley McGee, Trudy Leong

1. **Author affiliation and conflict of interest details**
* Lesley Robertson, Department of Psychiatry, University of the Witwatersrand: no conflicts of interest related to olanzapine
* Tamara Kredo, Cochrane South Africa, South African Medical Research Council; Division of Clinical Pharmacology, Department of Medicine, and Division of Epidemiology and Biostatistics, department of Global Health, Stellenbosch University: no conflicts of interest related to olanzapine
* Mashudu Mthethwa, Cochrane South Africa, South African Medical Research Council: no conflicts of interest related to olanzapine
* Natasha Gloeck, Cochrane South Africa, South African Medical Research Council: no conflicts of interest related to olanzapine
* Shelley McGee, Ophthalmological Society of South Africa: no conflicts of interest related to olanzapine
* Trudy Leong, Right-To-Care as Secretariat-support to PHC/ Adult Hospital Level Committee of the National Essential Medicines List, NDoH: no conflicts of interest related to olanzapine
1. **Introduction/ Background**

The *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (DSM-5)4 describes delirium as an acute disturbance in attention, awareness (reduced orientation to the environment), and cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception). It develops within hours to days and tends to fluctuate during the day, worsening in the evenings. Delirium may be ‘hyperactive’, with increased mood lability, agitation, and/or uncooperative behaviour, or ‘hypoactive’, with poor responsiveness and stupor.

Delirium is a physiological consequence of another medical condition, substance intoxication or withdrawal, exposure to a toxin, or multiple aetiologies. Treatment of delirium necessitates treatment of the underlying cause. Non-pharmacological measures to reduce confusion include a calm, predictable care environment, effective communication, verbal reorientation, and maintenance of the circadian rhythm. Medicine management of agitation, distress, or uncooperative behaviour may be necessary to facilitate nursing and treatment of the underlying condition. Currently, haloperidol, IM is recommended if non-pharmacological measures are insufficient. Haloperidol IM 5mg/ml and 20mg/2ml have been discontinued in South Africa by Pfizer and no other supplier has been identified.

1. **Purpose/Objective i.e., PICO question**:
* **Population**

People ≥18 years treated for delirium (formally diagnosed using a validated tool) or sub-syndromal delirium (presence of some delirium symptoms) in an acute care (e.g., primary health clinic/ community health clinic/ hospital emergency room, medical or surgical ward), intensive care, or palliative care setting. Exclude studies solely focusing on people with substance intoxication or withdrawal or people in psychiatric care settings.

* **Intervention**

Olanzapine IM and orodispersible tablets, any dose

* **Comparators**

Haloperidol IM +/- promethazine IM, any dose

Benzodiazepines: any dose, given orally or IM

Placebo

* **Outcomes**

Efficacy

* Duration of delirium (days)
* Change in delirium severity, assessed by validated instruments.
* Change in agitation score
* Delirium resolution (defined as reduction of delirium rating scale below a target set by the authors or complete resolution of symptoms)
* Use of physical restraint
* Other – hospital/ intensive care unit (ICU) length of stay (days), hospital discharge disposition (e.g., rehabilitation, chronic care facility, home), health-related quality of life (as reported by study authors)

Safety

* Extrapyramidal side effects (EPS); use of anticholinergic medication
* Adverse events as defined by the study authors (e.g., prolongation of the QTc interval, sudden cardiac death, cerebral vascular events, seizures, extrapyramidal effects, long-term cognitive impairment (e.g., change in Mini Mental Status Exam or as reported by study authors))
* Mortality
* **Study types**

Clinical practice guidelines, health technology assessments, systematic reviews of randomised controlled trials (RCTs), RCTs and, if the latter is unavailable, systematic reviews of non-randomised/ observational studies or observational studies. Ongoing trials were also sought.

**Methods:**

* 1. **Data sources**:

Clinical Practice Guidelines sources searched were the Guidelines International Network (GIN) Library, the National Institute for Health and Care Excellence (NICE) and the British Association of Clinical Pharmacology, as well as relevant clinical practice guidelines from Australia, New Zealand and Canada on their government websites, searched via Google.Systematic reviews and randomised controlled trials were sought in PubMed, the Cochrane Library, and Epistemonikos*.*

* 1. **Search strategy –** A search strategy was developed for PubMed and adapted to other databases (Appendix 1). A search for systematic reviews and RCTs was conducted on PubMed, the Cochrane Library, and Epistemonikos on 4 March 2022 (Appendix 1). The search was inclusive of all populations (with acute agitation or delirium) as the two review topics were happening in parallel and this was most efficient approach for searching and screening.

**Screening, data extraction and analysis, evidence synthesis:** Records were uploaded into the reference management software, COVIDENCE. Titles and abstracts were screened independently and in duplicate (NG, MM, TK, LR). Thereafter, full text screening was done by two reviewers, including tagging the study design (RCT or SR) and the population (delirium or acute agitation) and checked by a third reviewer. Discrepancies were discussed with LR and TK to finalise selection. We took a step-wise approach, screening for systematic reviews first and then for RCTs. Data extraction for included reviews was done by one reviewer and checked by a second reviewer. Eligible clinical guidelines were appraised with the AGREE II tool by two reviewers (MM and NG). Eligible systematic reviews were appraised using the AMSTAR II Checklist, and eligible RCTs were assessed for Risk of Bias using the Cochrane’s RoB 2.0 Tool. Data was extracted into Characteristics of Included studies tables (tables 2 and 3).  For dichotomous outcomes, we reported risk ratios (RR) with 95% confidence intervals (CI). We reported results from the review or trial where possible. Despite the intervention in these studies being haloperidol, and olanzapine being the comparator, outcomes of results were not reanalysed in RevMan to align with the review question as denominators for the systematic reviews were not available and we wanted to keep the results standardised. Where available, we reported on the GRADE (level of certainty) of the evidence.

* 1. **Excluded studies:** Reasons for excluding full-texts were agreed in duplicate with a third reviewer finalizing any disputes.

**Results:**

1. Search results

We searched PubMed, Epistemonikos and the Cochrane Library on 4 March 2022. We identified 778 records which were imported for screening, with 147 duplicates removed. Furthermore, three records were identified from experts in the field and three were identified through reference searching. We screened 636 abstracts, of which 541 were irrelevant. 95 full-text studies were assessed for eligibility; 86 studies were excluded. There were nine included studies: two systematic reviews, three RCTs and four ongoing studies.

The Prisma Flow Chart is available in Appendix 2.

1. Description of included clinical guidelines, systematic reviews and RCTs

Table 1 reports a summary of the guidelines, Table 2 reports the main characteristics and outcomes of the included systematic reviews, and Table 3 reports the main characteristics and outcomes of included randomised controlled trials. Appendix 2 describes the excluded studies and Appendix 3 provides a summary of ongoing trials.

* 1. **Clinical guidelines:**

We identified three guidelines

1. National Institute for Health and Care Excellence (NICE). Delirium: diagnosis, prevention and management6
2. Scottish Intercollegiate Guidelines Network (SIGN). Risk reduction and management of delirium7
3. Victorian Government Department of Human Services. Clinical practice guidelines for the management of delirium in older people8

Following appraisal with AGREE II, all three were assessed as moderate to good quality (see Table 1). The NICE guideline was first issued in July 2010, and updated in March 2019. This guideline offers guidance around modifiable risk factors to identify people at risk of developing acute delirium, diagnosis of delirium in long-term, critical and acute care settings, and pharmacological as well as non-pharmacological interventions for reducing delirium incidence and consequences, and reducing the severity, duration and consequences of delirium in adults (18 years and older) in a hospital or long-term residential care. This guideline had an overall AGREE II score of 83%. Of note is that olanzapine was removed from the updated NICE guideline (2019), as haloperidol now has UK marketing authorisation for delirium treatment (though, discontinued from the South African market).

The SIGN delirium guideline was first published in March 2019. This guideline provides guidance for reducing the risk of delirium, as well as the detection, assessment, treatment and follow up of adults with delirium in all settings (patient homes, long term care, hospitals, and hospices). This guideline had an overall AGREE II score of 67%.

The Victorian Government Department of Human Services’ guideline for the management of delirium in older peoplewas published in 2006 and provides recommendations in the assessment and management of older people (65 years and older, or 45 years and older in in Aboriginal and Torres Strait Islander people) in Australia in hospitals, and across healthcare settings, as well as the prevention of delirium in at-risk older people, identifying and defining appropriate health service provision and management options to ensure the best possible health outcomes. This guideline had an overall AGREE II score of 83%.

Recommendations related to this review (olanzapine vs haloperidol) are summarized in Table 1. Domain scores for the AGREE II Appraisals can be found in Appendix 3.

**Table 1: Summary of Guidelines and AGREE II scores**

|  |  |  |
| --- | --- | --- |
| **Name** | **Recommendation** | **AGREE II** |
| National Institute for Health and Care Excellence (NICE). **Delirium: diagnosis, prevention and management** | The NICE group recommends that if a person with delirium is distressed or considered a risk to themselves or others and verbal and non-verbal de-escalation techniques are ineffective or inappropriate, consider giving short-term (usually for 1 week or less) *haloperidol or olanzapine*, starting at the lowest clinically appropriate dose and titrating cautiously according to symptoms (conditional, very low certainty evidence)In the most recent review of this guidance (2019) olanzapine was removed as a treatment option in favour of haloperidol, which had achieved authorisation for the indication of delirium in the United Kingdom. | 83%  |
| Scottish Intercollegiate Guidelines Network (SIGN). **Risk reduction and management of delirium**.  | The SIGN group states “Because the studies identified are underpowered, larger trials are needed before recommendations can be made on the use of antipsychotics for the treatment of patients in ICU with delirium.” (1++ - High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias) | 67%  |
| Victorian Government Department of Human Services. **Clinical practice guidelines for the management of delirium in older people.**  | The Victorian Government Department of Human services recommends that antipsychotic medication should only be used for the treatment of severe behavioural disturbances and or severe emotional disturbances when there is clear intent for its use (e.g. severe agitation interfering with sleep-wake cycle). When used, “Titrated antipsychotics need to be closely monitored by nursing and medical staff. The dosage and frequency should be titrated carefully against the level of agitation at each review. Titration must commence from a low dose typically commencing with the equivalence of 0.25-0.50mg of haloperidol; olanzapine 2.5 mg orally; or risperidone 0.25 mg orally.” (III-2 – a comparative study with concurrent controls (non-randomised experimental trial, cohort study, case-control study, interrupted time-series with a control group)) | 83%  |

**2.2 Systematic reviews**

We identified two systematic reviews for inclusion

1. Finucane 2020. Drug therapy for delirium in terminally ill adults9
2. NICE Review within the NICE guideline6

Finucane 20209, a Cochrane Systematic Review, reviewed evidence of pharmacological therapy for delirium management in terminally ill adults (including terminal agitation, distress or restlessness). The setting was not specified. The NICE review6 reviewed delirium management in hospitalized participants (age 18 years or older) regardless of whether in a surgical, medical, ICU and emergency ward, mental health settings, and long-term care settings. In both reviews, delirium was defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5 or earlier criteria).

Primary outcomes assessed in Finucane 2020 were 1) delirium symptoms within 24 to 48 hours, 2) agitation score within 24 to 48 hours and 3) the number of adverse events (including extrapyramidal side effects). Secondary outcomes included 1) the use of any rescue medication (such as midazolam), 2) cognitive status and 3) survival.

Primary outcome measures in the NICE review were 1) duration of delirium and 2) number recovered from delirium. The secondary outcomes included 1) severity of delirium, 2) length of stay, 3) incidence of cognitive impairment or dementia, 4) number of patients in hospital discharged to new long-term care placement, 5) mortality, 6) number of patients with persisting delirium, 7) quality of life (patient), 8) quality of life (carer), and 9) adverse effects associated with the intervention (including extrapyramidal side effects). Outcome results are summarised in Table 2.

There was only one included RCT (Lin 2008) in Finucane 2020 that compared haloperidol to olanzapine. The full text for the included RCT was not found despite extensive searching (searching online databases, contacting trial and review authors). Two outcomes of interest were reported in this RCT and are further detailed in Table 2.

Within the NICE review, olanzapine was considered in two comparisons: olanzapine versus no treatment (one RCT, Hu 2006 – 103 participants, full text not available for review) and haloperidol versus olanzapine (Hu 2006 and Skrobik 2004, Skrobik 2004 is summarized below under the RCTs, Table 3). Finucane 2020 had a moderate AMSTAR II rating. The quality was marked down as authors did not explain their selections of study designs included in the review.   The NICE review had a high AMSTAR II rating of 4. GRADE evidence ratings are summarized in Table 2.

**2.3 RCTs**

We identified three randomised controlled trial for inclusion

* 1. Skrobik 2004. Olanzapine vs haloperidol: treating delirium in a critical care setting10
	2. Jain 2017. Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium11
	3. Van der Vorst 2020. Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer: a phase III randomized clinical trial12

The trials were conducted in three countries (Canada (one site), India (one site) and The Netherlands (five sites)). Sample sizes varied from 73 to 100 participants and took place in a medical-surgical ICU (Skrobik 200410), medical emergency wards (Jain 201711) and a medical oncology ward or high-care hospice facility (van der Vorst 202012). All three trials compared haloperidol to olanzapine. In Skrobik 2004, participants were randomised to haloperidol, initiated at 2.5 to 5mg 8 hourly (either orally or via an enteral tube) or olanzapine at 5mg daily. Older patients (60 years and above) received a lower starting dose (haloperidol 0.5 to 1mg, olanzapine 2.5mg). Titration thereafter was based on clinician judgment. In Jain 2017, the mean daily doses of olanzapine and haloperidol were 5.49mg (range 2.5mg) and 2.10mg (range 1 to 5mg) respectively. Doses were determined by the participants’ Memorial Delirium Assessment Scale (MDAS) score. In van der Vorst 2020, dosing was age-adjusted and based on clinical practice guidelines. Patients under 75 years old were started on haloperidol 1mg or olanzapine 5mg. This was titrated every 40min for haloperidol and two hours for olanzapine, according to the delirium observation scale (DOS) to a maximum on day 1 of 20mg po or 10mg subcutaneously (sc) for haloperidol, and 20mg po or IM for olanzapine. The doses were halved for patients 75 years and older.

Jain 2017 reported on duration of delirium (days). Skrobik 2004, Jain 2017 and van der Vorst 2020 reported on change in delirium sensitivity – however, the three trials used different instruments of measuring this outcome and so we could not compare in meta-analysis (Skrobik 2004 used change in delirium index scores, Jain 2017 used mean MDAS scores at baseline and at the end of the study period, and van der Vorst used delirium response rate (DRR) as defined by Delirium Rating Scale-R-98 (DRS-R-98) assessment). Van der Vorst 2020 reported on delirium resolution (days). In terms of safety outcomes, Skrobik 2004 and van der Vorst 2020 reported on extrapyramidal side effects. Jain 2017 and van der Vorst 2020 reported on adverse events.

Two of the trials (Skrobik 2004 and Jain 2017) were rated as having a high risk of bias. Skrobik 2004 was rated high due to quasi-randomization of allocation sequence and baseline differences between allocation groups, no information around participant blinding and effects of assignment, no information around a prespecified plan or protocol. Jain 2017 was rated high due to this being a single-blind study, limited information on statistical methods, no information around data available for all participants and missingness, potential bias from researchers not being blinded, and no information around a pre-specified analysis plan. Van der Vorst 2020 was rated as having some concerns of bias due to no information around pre-specified plan or protocol.

1. **Description of excluded studies**

We excluded 86 full texts – 41 for wrong indication, 16 were awaiting classification, 10 for wrong study design, 7 for wrong intervention, 5 for wrong patient population, 3 for wrong outcomes, 3 for wrong language and 1 registered trial was stopped with recruitment issues. The excluded studies with reasons are listed in Appendix 2.

 **EFFECTIVENESS OF THE INTERVENTION**

|  |  |
| --- | --- |
| **Comparison** | **Number of studies** |
| 1. Olanzapine vs Haloperidol | 2 systematic reviews with 2 relevant RCTS and 2 additional RCTs  |
| 2. Olanzapine vs Benzodiazepines | 0 studies identified |
| 3. Olanzapine vs Placebo | 1 systematic review with 1 RCT |

**Comparison 1: Olanzapine vs Haloperidol**

**Efficacy**

*Critical outcomes:* None of the 5 included studies reported on the following outcomes:

* change in agitation score,
* use of physical restraint,
* hospital/ICU length of stay,
* hospital discharge disposition and
* health related quality of life

*Important outcomes*

1. **Duration of delirium** **(days):**
	* *NICE review 2010 (updated in 2019):* The effect of haloperidol compared to olanzapine on duration of delirium is uncertain. Mean Difference (MD) 0.62 days, 95% CI 0.06 to 1.18, one RCT, n = 146, 1 trial, very low certainty evidence due to study quality, and imprecision
	* *Jain 2017:* The mean duration of treatment (days) was similar, 3.57 days (+- 0.92 days) in the olanzapine arm and 3.37 days (+- 0.71 days) in the haloperidol arm.
2. **Change in delirium severity:**

Results were reported from three studies at different time points and using different measures. Overall, they found there was no difference in delirium severity between olanzapine and haloperidol.

* + *Finucane 2020:* Change in delirium severity: there may be little or no difference in change in delirium severity with olanzapine compared to haloperidol (Very low certainty evidence due to critical imprecision)

1) within 24 hours: the mean difference (MD) between treatment arms was 2.36 (95% CI -0.75 to 5.47).

2) between 24 and 48hrs: MD 1.90 (95% CI -1.50 to 5.30)

* + *NICE review:* There may be no difference in change in delirium severity score (delirium Rating Scale – DRS) comparing haloperidol and olanzapine. MD 0.7, 95% CI 0.45 to 1.85, n =146, 1 trial, moderate certainty evidence rated down due to poor study quality)
	+ *Skrobik 2004:* There was a comparable reduction in the DI score in both groups over time (ANOVA time effect p 0.02, group effect p 0.83, interaction effect p 0.64)
	+ *Jain 2017:* the mean MDAS score at baseline was 18.49 in the olanzapine group and 17.79 in the haloperidol group (the groups were comparable at baseline, p 0.791). The mean MDAS score at the end of the study period was 8.43 in the olanzapine group and 8.00 in the haloperidol group.
	+ *Van der Vorst 2020:* The delirium response rate (DRR) was in the Olanzapine arm was 45% (95% CI 31 to 59) and 57% (95% CI 43 to 71) in the haloperidol arm (ΔDRR −12%; odds ratio [OR], 0.61; 95% CI, 0.2–1.4)
1. **Delirium resolution** (defined as reduction of delirium rating scale below a target set by the authors or complete resolution of symptoms): Results were reported from three studies. Overall, they found there was little or no difference in delirium resolution between olanzapine and haloperidol.
	* *NICE review:* There may be little to no difference comparing haloperidol and olanzapine. Risk Ratio (RR) 0.99, 95% CI 0.8 to 1.21, p=0.24, I2=27%, n = 218, 2 trials (low certainty evidence due to poor study quality and indirectness from delirium assessment).
	* *Van der Vorst 2020:* The TRR (time from randomisation to resolution) was 4.5 days (95% CI 3.2 to 5.9) in the Olanzapine and 2.8 days (95% CI 1.9 to 3.7) in the haloperidol arm.

**Safety**

1. **Mortality**
* Not reported.
1. **Extrapyramidal side effects (EPS):**
	* *NICE review:* We are uncertain about the difference in occurrence of EPS between haloperidol and olanzapine groups, RR 8.2, 95% CI 0.48 to 140.09, n = 73 , 1 quasi-RCT (very low certainty evidence due to study design limitations, and imprecision). Six participants rated low scores on extrapyramidal symptom testing (1 for the Ross Chouinard, 1–4 for the Simpson-Angus scale) in the haloperidol arm. There were no extrapyramidal manifestations in the olanzapine arm.
	* *Van der Vorst 2020:* six participants (12.2%) experienced EPS in the haloperidol group (three with tremors, two with muscle stiffness and one with QTc prolongation), compared to four (8.2%) in the olanzapine group (two with tremors, one with dizziness and one with muscle stiffness).
2. **Requiring anticholinergic medication:**
	* *Skrobik 2004:* no participants in either the haloperidol or olanzapine groups received prophylactic or therapeutic antiparkinsonian therapy.
3. **Adverse events:**
	* *Jain 2017:* There were two participants in the olanzapine group with adverse effects (one with excessive sedation, one with akathisia), and three in haloperidol group (drug-induced parkinsonism). All side effects were mild in severity. EPS were not defined separately but included under adverse events and as such have been reported here.
	* *Van der Vorst 2020:* 13 out of 46 patients (26.5%) in the olanzapine arm and 16 out of 49 patients (32.7%) in the haloperidol arm reported treatment-related adverse effects of any grade. Five patient (10.2%) in the olanzapine group and 10 patients (20.4%) in the haloperidol group reports Grade 3 or above TRAEs (OR 0.4, 95% CI 0.1 to 1.4, p=0.16). There were no treatment-related deaths.

**Comparison 2: Olanzapine vs Benzodiazepines**

None of the included studies compared olanzapine to benzodiazepines

**Comparison 3: Olanzapine vs Placebo (NICE review)**

**Efficacy**

*Critical outcomes*: The NICE review did not report on the following outcomes:

* change in agitation score
* use of physical restraint, hospital/ICU length of stay
* hospital discharge disposition and
* health related quality of life.

*Less critical outcomes:*

1. **Duration of delirium (days):** We are uncertain of the effect of olanzapine compared to placebo on duration of delirium MD=-2.4, 95% CI -3.51,-1.29, n = 103, 1 trial. (Low certainty evidence due to very poor study quality and imprecision)
2. **Change in delirium severity**: There is probably a reduction in the delirium rating scale (DRS) in favour of olanzapine compared to placebo MD = -11.1, 95% CI -15.51 to -7.69, n=103, 1 trial. (Moderate certainty evidence due to poor study quality and imprecision)
3. **Delirium resolution** (defined as reduction of delirium rating scale below a target set by the authors or complete resolution of symptoms): Outcome “Complete Response” reported that there is probably a more rapid resolution of delirium symptoms in favour of the olanzapine compared to placebo, RR=3.68, 95% CI 1.63 to 8.33, n=103, 1 trial. (Moderate certainty evidence due to poor study quality, indirectness and imprecision)

**Safety**

For this comparison, the NICE review did not report on extrapyramidal side-effects, if anticholinergic medication was required, drug-related adverse events or mortality.

**Conclusion**

We identified two reviews and three trials addressing the outcomes of interest, comparing olanzapine to haloperidol. In patients with delirium, there is probably little or no difference in olanzapine compared to haloperidol in the outcomes of interest. We are uncertain about the difference in occurrence of extrapyramidal side-effects and other adverse events in olanzapine compared to haloperidol.

We identified one review addressing the outcomes of interest, comparing olanzapine to placebo. In patients with delirium, we are uncertain of the effect of olanzapine compared to placebo in duration of delirium. There is probably a reduction in the delirium rating scale and a more rapid resolution of delirium symptoms in favour of olanzapine compared to placebo. There were no data on any safety outcomes.

Due to small study sizes and methodological limitations in the studies, the evidence was generally of low to very low certainty. This indicates a research gap. Larger rigorous RCTs are needed.

**Table 2: Characteristics of Included Systematic Reviews: Delirium**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CITATION**  | **STUDY DESIGN**  | **POPULATION (N)**  | **INTERVENTION *vs*** **COMPARATOR**  | **OUTCOMES & MAIN FINDINGS**  | **COMMENTS**  |
| **Comparison 1: Haloperidol compared to Olanzapine**  |
| Finucane AM, Jones L, Leurent B, Samson EL, Stone P, Tookman A, et al. Drug therapy for delirium **in terminally ill adults**. Cochrane Database Sys. Rev. 2020;1. Doi: 10.1002/14651858.CD004770.pub3  | Systematic review | Terminally ill adults (18 years or older) with delirium symptomsIncluded studies: RCTs  | Olanzapine, oral compared to Haloperidol, oral | Delirium symptoms within 24 hoursn= 28, one trial mean difference (MD) 2.36 (95% CI -0.75 to 5.47, p=0.14)Delirium symptoms between 24 and 48 hoursn=24, one trialMD 1.9 (95% CI -1.5 to 5.3, p=0.27) **Very low certainty** (both outcomes), downgraded by 3 levels due to so few data that the results were highly susceptible to chance | AMSTAR – Moderate quality* Study design not explained
* No meta-analysis
 |
| NICE Review (within CPG)National Institute for Health and Care Excellence (NICE). **Delirium: diagnosis, prevention and management** [Internet]. [London]: NICE; 2010 [updated July 2020]. (Clinical guideline 103 [CG103]). Available from:<https://www.nice.org.uk/Guidance/CG103>  | Systematic review | Adult patients (18 years or older) in a hospital setting (surgical, medical, ICU, or emergency departments) or in long-term residential care with delirium.Included studies: RCTs and quasi randomized trials. Non-randomised studies (NRS) were included only if no other evidence, with preference to large cohort studies and comparative non-randomised designs.Exclusion criteria:Younger than 18 yearsReceiving end-of-life careIntoxication and or acute withdrawal from drugs or alcohol, with associated delirium | Haloperidol compared to olanzapine | Complete response (resolution)n=219, 2 trialsRR=0.99 (95% CI 0.8 to 1.21, p=0.24, I2=27%)**Low certainty** downgraded due to poor study quality (not blinded, inadequate sequence generation and allocation concealment, funding and outcome possibly inadequate) and imprecision.Duration of deliriumn=146, 1 trialMD=0.62 (95% CI 0.06 to 1.18)**Very low certainty**, downgraded for very poor study quality, imprecision and reported as “time to take effect” in responders only, likely to be biasedSeverity of Deliriumn=146, 1 trialMD=0.7 (95% CI 0.45 to 1.85)**Moderate certainty,** downgraded due to poor study quality (not blinded) and imprecision (number of patients < 400)Adverse eventsn=73, 1 included trialRR=8.2 (95% CI 0.48 to 140.09)**Very low certainty**, downgraded due to very poor study quality (quasi-randomised, not blinded) and imprecision( wide confidence interval)  | AMSTAR – High quality* Data extraction not in duplicate
 |
| **Comparison 2: Olanzapine vs placebo** |
| NICE Review (within CPG)National Institute for Health and Care Excellence (NICE). **Delirium: diagnosis, prevention and management** [Internet]. [London]: NICE; 2010 [updated July 2020]. (Clinical guideline 103 [CG103]). Available from:<https://www.nice.org.uk/Guidance/CG103>  | Systematic review | Adult patients (18 years or older) in a hospital setting (surgical, medical, ICU, or emergency departments) or in long-term residential care with delirium.Included studies: RCTs and quasi randomized trials. Non-randomised studies (NRS) were included only if no other evidence, with preference to large cohort studies and comparative non-randomised designs.Exclusion criteria:Younger than 18 yearsReceiving end-of-life careIntoxication and or acute withdrawal from drugs or alcohol, with associated delirium | Olanzapine compared to placebo | Complete responsen=103, 1 included trialRR=3.68 (95% CI 1.63 to 8.33)**Moderate certainty** due to poor study quality (not blinded) indirectness (indirect outcome through delirium assessment method) and imprecision (number of events < 300).Duration of deliriumn=103, 1 included trialMD=-2.4 (95% CI 3.51 to -1.29)**Very low certainty** due to poor study quality (evidence of confounding and not blinded) and imprecision (wide confidence interval).Severity of Deliriumn=103, 1 included trialMD=-11.1 (95% CI 14.51 to -7.69)**Moderate certainty** due to poor study quality (not blinded) and imprecision (number of patients < 400). | AMSTAR – High quality* Data extraction not in duplicate
 |

**Table 3: Characteristics of Included Randomised Controlled Trials: Delirium**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **CITATION**  | **STUDY DESIGN**  | **POPULATION (N)**  | **INTERVENTION *vs*** **COMPARATOR**  | **OUTCOMES & MAIN FINDINGS**  | **RISK OF BIAS**   |
| **Comparison 1: Haloperidol versus Olanzapine** |
| Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a **critical care setting**. Intensive Care Med. 2004;30:444-9. Doi: 10.1007/s00134-003-2117-0  | Design Prospective quasi-randomized trial. Single blinding (treating nurses and physician not blinded to assigned drug) Duration July 2000 to September 2001.  Funding Peer-reviewed grant from the Zyprexa fund, Eli-Lilly, North America  Ethics Protocol approved by the institutional scientific and ethics committee  | Adults aged 18 to 75 years admitted to medical-surgical ICT in Montreal. All patients with delirium (as defined below) were considered eligible for the study.  Sample size 73 included in final analysis (Haloperidol n=45, Olanzapine n=28) 103 considered eligible, 80 informed consent obtained, 3 withdrawn, 2 status changed to “no active treatment”, 1 suspected drug interaction, 1 data lost  Inclusion criteria Admitted for more than 24 hours, participants screened 3 times daily for delirium with the ICU Delirium Screening Checklist (ICU-DSC). In participants with a score >= 4 or with clinical manifestations of delirium, diagnosis confirmed by physician using DSM-IV criteria.   Exclusion criteria Pregnant patients who received antipsychotic medication within 10 days prior to admission;Pregnant patients with contraindications to haloperidol or olanzapine; Gastrointestinal dysfunction that did not allow oral or enteral drug administration; Neurological status did not allow neuropsychiatric examination e.g. coma  Other caveats Patients who developed agitation were allowed intravenous haloperidol (“rescue haloperidol”)   | Intervention Enteral olanzapine 5mg daily (>60yrs: 2.5mg daily)  Comparator Enteral haloperidol 2.5 to 5mg every 8 hours (>60yrs: 0.5 to 1 mg 8 hourly)  Subsequent titration based on clinical judgement. Benzodiazepine use noted as adjuvant therapy.   | Outcomes1. Change in mean daily delirium scores (delirium index (DI) scores)
2. Adjunct benzodiazepine use requirements over time
3. Use of rescue haloperidol, opiates, sedatives, Ramsay scores, vital signs and liver function tests in both groups.
4. Presence of extrapyramidal side effects (EPS)

Results 1. Comparable reduction in DI score over time was noted in both groups, with no difference (ANOVA time effect p=0.02, group effect p=0.83 interaction effect p=0.64)
2. Benzodiazepines: Analysis of variance did not identify any difference between the two groups, at any of the 5 measurement times (interaction effect p=0.94 group effect p=0.9).
3. “ The dose of rescue haloperidol, opiates, sedatives other than benzodiazepines, Ramsay scores, vital signs, and liver function tests were no different between groups.”
4. Haloperidol: 6 rated low scores on extrapyramidal symptom testing (1 for the Ross Chouinard, 1–4 for the Simpson-Angus scale).

Olanzapine: no extrapyramidal manifestations or adverse effects  | **HIGH RISK OF BIAS**  All outcomes: **High risk of bias** in domain 1 due to quasi-randomisation of allocation sequence and baseline differences between allocation groups, **some concerns** in domain 2 due to no information around participant blinding and effects of assignment, and **some concerns**  in domain 5 due to no information around a prespecified plan or protocol. **Low risk of** **bias** in domains 3 and 4. |
| Jain R, Arun P, Sidana A, Sachdev A. Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium. Indian J Psychiatry. 2017;59(4):451-6. Doi:  10.4103/psychiatry.IndianJ Psychiatry\_59\_17  | Design Open label, randomized controlled study. Randomisation through computer-generated random number table Duration December 2011 to December 2012. Patients assessed every 24 hours until delirium resolution.  Trial registry Registered with the Clinical Trial Registry‑India CTRI/2016/10/007331  Ethics Approved by local institutional ethics committee  Funding None  Other Assessment of delirium through Confusion Assessment Method (CAM), and diagnosis using DSM-IV criteria. Delirium severity assessed with Memorial Delirium Assessment Scale (MDAS). Simpson-Angus Scale (SAS) used to assess EPS  | Delirious patients admitted to medicine emergency ward and referred to the Department of Psychiatry for consultation at the Government Medical College and Hospital, Chandigarh, India.  Sample Size 100 132 enrolled; 32 dropped out after randomization and were not included in the final analysis; Olanzapine n=47 Haloperidol n=53 Inclusion criteria Delirious patient plus >18 years old; Verbally responsive; No dementiaExclusion criteria Mechanically ventilated;Mute;Currently on antipsychotics for any reason;Experiencing alcohol or benzodiazepine withdrawal delirium; Hypersensitivity to either olanzapine or haloperidol in the past. | Intervention Olanzapine, enteral only, 2.5 to 10mg daily orally or via nasogastric tube (NGT)  Comparator Haloperidol, enteral only, 1 to 4mg orally or via NGT tube  Doses based on MDAS scores of mild, moderate or severe delirium.  | Outcomes 1. Efficacy of olanzapine and haloperidol in delirium
2. Tolerability of olanzapine and haloperidol in delirium
3. Phrenology of delirium and pattern of symptom improvement with treatment

 Results * Delirium severity – mean MDAS score (baseline) 18.49 olanzapine group, 17.79 haloperidol group (groups comparable at baseline, p=0.791). mean MDAS score (end study period) 8.43 olanzapine group, 8.00 haloperidol group; 54.7% reduction in mean MDAS scores (54.4% in olanzapine group and 55% in haloperidol group
* Pattern of symptom improvement
* Severity of attention on day 2 and severity of disorganized thinking on days 2 and 3 were less in the olanzapine group (p<0.05).
* Severity of perceptual disturbances on day 4, and severity of psychomotor disturbances on days 3 and 4 were less in the haloperidol group (p<0.05).
* Duration of treatment– mean duration of treatment (days) 3.57 olanzapine (+- 0.92 days), 3.37 haloperidol (+- 0.71 days), (p=0.233)
* Drug-related adverse effects – 2 in olanzapine group (1 with excessive sedation, 1 with akathisia), 3 in haloperidol group (drug-induced parkinsonism). All side effects were mild in severity.
 | **HIGH RISK OF BIAS**  All outcomes: **Some concerns** in domain 1 due to this being a single-blind study, **some concerns** in domain 2 due to single-blind study and limited information on statistical methods, **high risk of bias** in domain 3 due to no information around data available for all participants and missingness, **high risk of bias** in domain 4 due to potential bias from researchers not being blinded, and **some concerns** domain 5 due to no information around a pre-specified analysis plan.   |
| Van der Vorst MJDL, Neefjes ECW, Boddaert MSA, Verdegaal BATT, Beeker A, Teunissen SCC, et al. Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer: a phase III randomized clinical trial. Oncologist. 2020; 25:e570-7. Doi: https://doi.org/10.1634/theoncologist.2019-0470 | DesignMulticentre, randomized controlled, phase III trial. Conducted at five sites in the Netherlands. Study terminated early as unlikely to reach the predefined efficacy criteria.Trial registryNCT01539733DurationJanuary 2011 to July 2016FundingNetherlands Organization for Health Research and Development (ZonMw) Palliative Care Program (No. 11510011).EthicsWritten informed consent  | Patients ≥ 18 years old with advanced cancer, admitted to a medical oncology ward or high-care hospice facilitySample size 10050 allocated to each groupOlanzapine – 9 discontinued treatment. Analysis – Intention-to-treat (ITT) n=49, per protocol n = 40Haloperidol – 8 discontinued treatment. Analysis – ITT n = 49, per protocol n = 41Inclusion criteria18 years or older;Advanced cancer;Admitted to medical oncology ward or high-care hospice facility;Fluent in the Dutch language;Diagnosed with delirium.Exclusion criteriaDiagnoses of glaucoma, Parkinson’s disease, dementia or psychiatric disorders interfering with delirium assessment;history of neuroleptic malignant syndrome or convulsions;delirium due to substance withdrawal cardiac conduction abnormalities;Currently using other neuroleptic medication or lithium. | InterventionOlanzapine, po or IMIComparatorHaloperidol, po or sc | Outcomes:*Primary endpoint:* Delirium Response Rate (DRR) on days 1 to 7 after randomization as defined by DRS-R-98 assessment*Secondary endpoints:* TRR (time from randomization to resolution of delirium in days)TRAEs (treatment related adverse events), according to the CTCAE version 4.03Delirium-related distress for patients and their caregivers assessed by DEQResultsDRR: Olanzapine 45% (95% CI 31 to 59)  Haloperidol 57% (95% CI 43 to 71) (ΔDRR −12%, odds ratio [OR] 0.61,  95% CI 0.2–1.4 p = 0.23) (ITT)TRR: Olanzapine 4.5 days (95% CI 3.2 to 5.9) Haloperidol 2.8 days (95% CI 1.9 to 3.7) (p = 0.18)DRR for motor subtypes (ITT)Hyperactive OR 0.5, 95% CI 0.1 to 2.1, p=0.50Hypoactive OR 0.2, 95% CI 0.04 to 1.5, p=0.12Mixed OR 1.8, 95% CI 0.4 to 7.9, p=0.49SafetyTRAEs of any grade Olanzapine arm: 13 patients (26.5%) Haloperidol arm: 16 patients (32.7%)Grade ≥3 TRAEs Olanzapine arm: 5 patients (10.2%) Haloperidol arm: 10 patients (20.4%) (OR 0.4, 95% CI 0.1 to 1.4, p=0.16) No treatment related deathsDelirium-Related DistressSixteen patients completed this DEQ in each treatment arm.Mean delirium-related distress level (0 – 4 numerical rating scale) Olanzapine 2.1 (SD 1.4) Haloperidol 2.3 (SD 1.4)Mean delirium-related distress level (spouse/caregiver) Olanzapine 3.0 (SD 1.2) Haloperidol 2.7 (SD 1.1)Mean delirium-related distress level (nurses) Olanzapine 1.1 (SD 1.1) Haloperidol 0.9 (SD 0.9) | **SOME CONCERNS**All outcomes: **Some concerns** in domain 5 due to no information around pre-specified plan or protocol. **Low risk of bias** in domains 1 to 4. |

### Evidence to decision framework

|  | **JUDGEMENT** | **EVIDENCE & ADDITIONAL CONSIDERATIONS** |
| --- | --- | --- |
| **QUALITY OF EVIDENCE OF BENEFIT** | **What is the certainty/quality of evidence?**

|  |  |  |  |
| --- | --- | --- | --- |
| High | Moderate | Low | Very low |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

*High quality:* confident in the evidence*Moderate quality:* mostly confident, but further research may change the effect*Low quality:* some confidence, further research likely to change the effect*Very low quality:* findings indicate uncertain effect | For important outcomes there were limitations in the data: small study sizes, methodological limitations in the studies, the evidence was generally of low to very low certainty. No data on critical outcomes. |
| **EVIDENCE OF BENEFIT** | **What is the size of the effect for beneficial outcomes?**

|  |  |  |  |
| --- | --- | --- | --- |
| Large | Moderate | Small | None |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

|  |
| --- |
|  |

 |

 | Olanzapine vs haloperidol: no difference (none)Olanzapine vs placebo: probably better efficacy (small and low levels of certainty)Olanzapine vs benzodiazepines: no data |
| **QUALITY OF EVIDENCE OF HARM** | **What is the certainty/quality of evidence?**

|  |  |  |  |
| --- | --- | --- | --- |
| High | Moderate | Low | Very low |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

*High quality:* confident in the evidence*Moderate quality:* mostly confident, but further research may change the effect*Low quality:* some confidence, further research likely to change the effect*Very low quality:* findings indicate uncertain effect | For important outcomes there were limitations in the data: small study sizes, methodological limitations in the studies, the evidence was generally of low to very low certainty. No data on critical outcomes |
| **EVIDENCE OF HARMS** | **What is the size of the effect for harmful outcomes?**

|  |  |  |  |
| --- | --- | --- | --- |
| **L**arge | Moderate | Small | None |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

|  |
| --- |
|  |

 |

 | Olanzapine vs haloperidol: no difference (none)Olanzapine vs placebo: probably better efficacy (small)Olanzapine vs benzodiazepines: no data |
| **BENEFITS & HARMS** | **Do the desirable effects outweigh the undesirable harms?**

|  |  |  |
| --- | --- | --- |
| Favours intervention | Favours control | Intervention= Control *~~or~~* ~~Uncertain~~ |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

 | Olanzapine vs haloperidol: no difference (intervention = control)Olanzapine vs placebo: probably better efficacy (favours intervention) – but very low level of certainty of evidenceOlanzapine vs benzodiazepines: no data |
| **THERAPEUTIC INTERCHANGE** | Therapeutic alternatives available: N/A |  |
| **FEASABILITY** | **Is implementation of this recommendation feasible?**

|  |  |  |
| --- | --- | --- |
| Yes | No | Uncertain |
|

|  |
| --- |
| X |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

 | Olanzapine is not specifically registered for delirium; however, olanzapine oral is available in the public sector for other indications (bipolar disorder, schizophrenia). All formulations are available on the South African market.The loss of IM haloperidol is disruptive in the change of clinical practice. |
| **RESOURCE USE** | **How large are the resource requirements?**

|  |  |  |
| --- | --- | --- |
| More intensive | Less intensive | Uncertain |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

 | **Price of medicines:**

|  |  |  |  |
| --- | --- | --- | --- |
| **Medicine** | **Tender price (ZAR)\*** | **100% OF SEP (ZAR)\*\*** | **60% OF SEP (ZAR)** |
| Haloperidol 5mg tablets, 500 | 23.23 | n/a | n/a |
| Haloperidol 5mg/5ml injection, single (discontinued) | n/a | 45.68\*\*\* | n/a |
| Olanzapine 10 mg injection | n/a | 72.84 | 43.71 |
| Olanzapine 5mg orodipersible (ODT, 30 | n/a | 267.41 | 160.45 |
| Olanzapine 2.5mg tablet (SOT), 28 | 13.80 | n/a | n/a |

\* Contract circular HP09-2021SD, August 2022\*\*SEP database, July 2022\*\*\*SEP database, February 2021 (Haloperidol injection discontinued)**Background:*** *Adult Hospital Level STG and EML, 2019 edition*

Recommends haloperidol IM injection, but this has been discontinued from the South African market.* [*NICE Guideline 2010 (updated in March 2019)*](https://www.nice.org.uk/Guidance/CG103)

Recommendations for olanzapine include: * + IM injection: 2.5–10 mg per day, depending on response; the effect was observed for one week; delirium had 3 occurred from 30 min to 17 days ([Hu 2006](https://pubmed.ncbi.nlm.nih.gov/20473056/))
	+ Orally or by enteral tube: given within 2 h of the diagnosis of delirium, initially 5 mg per day (patients over 60 years 2.5 mg) then titrated based on clinical judgement for up to 5 days ([Skrobik 2004](https://pubmed.ncbi.nlm.nih.gov/14685663/))
	+ Orally/ sublingually: initial dose 1.25–2.5 mg then adjusted, depending on response, to 1.25–20 mg per day; the effect was observed for one week; delirium had occurred from 30 min to 17 days ([Hu 2006](https://pubmed.ncbi.nlm.nih.gov/20473056/))
* *NEMLC report* [*(Adult Hospital 2019 review of palliative care chapter)*](https://www.knowledgehub.org.za/content/standard-treatment-guidelines-and-essential-medicines-list)

|  |
| --- |
| *Haloperidol, oral: added* *Haloperidol, SC/IV: added**Lorazepam, oral: added* *Midazolam, SC/IV: added**Antipsychotic (haloperidol), oral/IV/SC: Low doses are generally recommended as 1strst line in guidelines, due to associated side-effects. However, a RCT (*[*Agar,2017*](https://pubmed.ncbi.nlm.nih.gov/27918778/)*) showed that oral haloperidol and risperidone was less effective in reducing delirium symptoms than placebo and shortened overall survival. Limitations included the oral route of administration (possibly contributing to increased extrapyramidal side effects); increased administration of midazolam to the antipsychotic groups (possibly increasing paradoxical agitation and variable baseline demographics and precipitants of delirium were not reported in all groups.* [*Cochrane review*](https://pubmed.ncbi.nlm.nih.gov/23152226/) *concluded that there is insufficient evidence to determine the role of medicine treatment for delirium in terminally ill patients; thus recommendations aligned with expert consensus.* ***Recommendation:*** *Low dose haloperidol as 1st line treatment for delirium in palliative care at secondary level of care.* *Rationale: Aligned with* [*guidelines.*](https://www2.gov.bc.ca/gov/content/health/practitioner%E2%80%90professional%E2%80%90resources/bc%E2%80%90)***Level of Evidence: III Guidelines*** |

* *Pharmacokinetic study by* [*Markowitz et al, 2006*](https://pubmed.ncbi.nlm.nih.gov/16432268/)

Both routes of ODT administration (above the tongue and sublingually) resulted in more measurable early concentrations relative to SOT. However, there were no statistically significant differences observed between any of the olanzapine exposures for observed pharmacokinetic parameters (C(max), T(max), AUC(0-8h)). * *Medicines.org.uk:* [*Olanzapine 5mg ODT tablets - Summary of Product Characteristics (SmPC)*](https://www.medicines.org.uk/emc/product/4772/smpc)

Olanzapine ODT should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed. Removal of the intact ODT from the mouth is difficult. Since the ODT is fragile, it should be taken immediately on opening the blister. Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice or milk) immediately before administration. Olanzapine ODT is bioequivalent to olanzapine film-coated tablets, with a similar rate and extent of absorption. It has the same dosage and frequency of administration as olanzapine film-coated tablets. Olanzapine ODT may be used as an alternative to olanzapine film-coated tablets.* *Pharmacokinetic parameters:*

On review of the pharmacokinetic properties of olanzapine ODT and SOT formulations, bioequivalence can be assumed.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Tmax** | **T1/2** |  |
| Haloperidol, IM | 10 minutes | 13 to 35 hrs | *SAMF, 2022* |
| Olanzapine ODT | 4 to 6 hrs | 33 hrs | *Markowitz, 2006* |
| Olanzapine SOT | 5 to 8 hrs | 33 hrs | *Callaghan JT, 1999* |
| Olanzapine, IM | 14 to 45 minutes | 33 hrs | *FDA PI (drugs.com)* |

**Comparative cost analysis per treatment course** *(comparing direct medicine prices):** **Haloperidol 0.5-1mg inj,** immediately 30 minutes later and 4-hourly to a max of 10mg per 24 hours *(Using the max dose of 2 x 5 mg inj per day for 3 days = 6 x 10 mg inj):* **R274.08** (Historic SEP price accessed through State S21)
* **Haloperidol 0.75–2.5 mg oral via NGT,** immediately 30-60 minutes later and 4-hourly to a maximum of 10mg per 24 hours *(Using the max dose of 3 x 5 mg tablets per day for 3 days = 9 x 5 mg tablets):* **R2.14** (Contract price)
* **Olanzapine 2.5-5mg inj**, immediately 30-60 minutes later and 4-hourly to a max of 20mg per 24 hours *(Using the max dose of 2 x 10 mg inj per day for 3 days = 6 x 10 mg inj):* **R437.06** (100% SEP) and **R262.24** (60% SEP).
* **Olanzapine 2.5-5mg SOT via NGT,** immediately 30-60 minutes later and 4-houlry to a max of 20mg per 24 hours *(Using the max dose of 8 x 2,5 mg tablets per day for 3 days = 24 x 2.5 mg tablets):* **R11.83** (Contract price)
* **Olanzapine 2.5-5mg ODT**, immediately 30-60 minutes later and 4-hourly to a max of 20mg per 24 hours *(Using the max dose of 4 x 5mg ODTs per day for 3 days = 12 x 5 mg ODT):* **R106.96** (100% SEP) and **R64.18** (60% of SEP)

**NB:** It is concerning to note that haloperidol injection had only been added to the NICE guidelines in 2019, as haloperidol was registered with the MHRA for delirium. Global vs local availability of medicines warrants investigation.**Other resources:** n/a |
| **VALUES, PREFERENCES,****ACCEPTABILITY** | **Is there important uncertainty or variability about how much people value the options?**

|  |  |  |
| --- | --- | --- |
| Minor | Major | Uncertain |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

**Is the option acceptable to key stakeholders?**

|  |  |  |
| --- | --- | --- |
| Yes | No | Uncertain |
|

|  |
| --- |
|  |

 |

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

 | There is no information available about the acceptability of olanzapine to stakeholders. However, given the absence of other options in the management of delirium, it could be a viable and acceptable alternative. |
| **EQUITY** | **Would there be an impact on health inequity?**

|  |  |  |
| --- | --- | --- |
| Yes | No | Uncertain |
|

|  |
| --- |
|  |

 |

|  |
| --- |
| X |

 |

|  |
| --- |
| X |

 |

 |  There is no available local survey data – based on expert opinion. |

|  |  |  |  |
| --- | --- | --- | --- |
| **Version** | **Date** | **Reviewer(s)** | **Recommendation and Rationale** |
| Initial | 18 August 2022 | LR, SM, TK, NG, MM, TL  | Olanzapine (all formulations) suggested as an option to haloperidol to manage delirium where non-pharmacological management is not sufficient (conditional recommendation, low to very low certainty evidence).  |

**References**

1. Du Plooy N, Day C, Manning K, Abdullah F, James K, Grace L, et al. Prevalence and outcome of delirium among acute general medical inpatients in Cape Town, South Africa. S Afr Med J. 2020;110(6):519-24.10.7196/SAMJ.2020.v110i6.14363

2. Day C, Manning K, Abdullah F, James K, Grace L, April C, et al. Delirium in HIV-infected patients admitted to acute medical wards post universal access to antiretrovirals in South Africa. S Afr Med J. 2021;111(10):974-80.10.7196/SAMJ.2021.v111i10.15628

3. Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. Ann Intern Med. 2019;10.7326/M19-1860.10.7326/M19-1860

4. American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.

6. National Institute for Health and Care Excellence (NICE). Delirium: diagnosis, prevention and management [Internet]. [London]: NICE; 2010 [updated July 2020; cited Feb 2022]. (Clinical guideline 103 [CG103]). Available from: https://www.nice.org.uk/Guidance/CG103

7. Scottish Intercollegiate Guidelines Network (SIGN). Risk reduction and management of delirium [Internet]. [Edinburgh]: SIGN; 2019. (SIGN publication no. 157) [updated March 2019; cited Feb 2022]. Available from: <https://www.sign.ac.uk/our-guidelines/risk-reduction-and-management-of-delirium/>

8. Victorian Government Department of Human Services. Clinical practice guidelines for the management of delirium in older people [Internet]. [Melbourne]: HCOASC; 2006 [cited Feb 2022]. Available from: <https://www.delirium.health.qut.edu.au/__data/assets/pdf_file/0006/858372/delirium-cpg.pdf>

9. Finucane AM, Jones L, Leurent B, Sampson EL, Stone P, Tookman A, et al. Drug therapy for delirium in terminally ill adults. Cochrane Database of Systematic Reviews, 2020, Issue 1. Art. No.: CD004770. DOI: 10.1002/14651858.CD004770.pub3.

10. Skrobik YK, Bergeron N, Humont N, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004 (3):444-9. DOI: 10.1007/s00134-003-2117-0

11. Jain R, Arun P, Sidana A, Sachdev A. Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium. Indian J Psychiatry. 2017(59):451-6. DOI: 10.4103/psychiatry.IndianJPsychiatry\_59\_17

12. Van der Vorst MJDL, Neefjes ECW, Boddaert MSA, Verdegaal BATT, Beeker A, Teunissen SCC, et al. Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer: a phase III randomized clinical trial. Oncologist; 2020(25):e570-7. DOI: 10.1634/theoncologist.2019-047

# **Appendix 1: Search Strategy**

|  |  |
| --- | --- |
| #9 | #1 AND #2 AND #8 |
| #8 | #3 OR #4 OR #5 OR #6 OR #7 |
| #7 | schizophrenia[mh] OR schizophreni\*[tiab] |
| #6 | dementia[mh] OR dementia\*[tiab] |
| #5 | confusion[mh] OR confus\*[tiab] OR disorientat\*[tiab] OR bewilderment[tiab] OR delirium\*[tiab] |
| #4 | paranoid disorders[mh] OR paranoi\*[tiab]  |
| #3 | psychotic disorders[mh] OR psychosis[tiab] OR psychotic[tiab] OR psychoses[tiab] OR psychiatric disorder\*[tiab] OR mental disorders[mh] OR mental illness\*[tiab] OR mental disorder\*[tiab] OR mood disorders [mh ] OR mood disorder\*[tiab] OR affective disorder\*[tiab] OR bipolar disorder[mh] OR bipolar[tiab] OR mania\*[tiab] OR manic[tiab] |
| #2 | Search: aggression[mh] OR aggress\*[tiab] OR disruptive behavior\*[tiab] OR disruptive behaviour\*[tiab] OR agitat\*[tiab] OR violent behavior\*[tiab] OR violent behaviour\*[tiab] |
| #1 | Search: olanzapine[mh] OR olanzapine\*[tiab] OR zyprexa\*[tiab] OR zolafren\*[tiab] OR LY 170053[tiab] OR LY170053[tiab] OR LY 170052[tiab] |

# **Appendix 2: PRISMA Flow Chart**

**Identification of studies via other methods**

**Identification of studies via databases**

Records identified from: expert in the field (n=3)

expert in the field (n=3)**Sourced from expert (n = 3)**

Records removed *before screening*:

**Duplicate records removed**

**(n = 147)**

Records identified from\*:

**Databases (n = 778)**

**Identification**

Records screened

**(n = 631)**

Records excluded

**(n = 541)**

Reports sought for retrieval

**(n = 95)**

Reports not retrieved

**(n = 0)**

**Screening**

Reports excluded:

Wrong intervention (n = 3)

**Reports excluded: (n = 86)**

41 Wrong indication

16 Awaiting classification

5 Wrong patient population

10 Wrong study design

3 Wrong outcomes

1 Registered trial, trial stopped for recruitment issues

7 Wrong intervention

3 Wrong language

**Ongoing studies: (n = 4)**

Reports assessed for eligibility

**(n = 3)**

Reports assessed for eligibility

**(n = 95)**

Studies included in review

**(n = 5)**

**Included**

*Modified From:*  Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <http://www.prisma-statement.org/>

# **Appendix 3: AGREE II Appraisal Summary**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Guideline**  | **Domain 1**  | **Domain 2**  | **Domain 3**  | **Domain 4**  | **Domain 5**  | **Domain 6**  | **OA**  |
| **NICE:** DELIRIUM: diagnosis, prevention and management  | 94% | 81% | 88% | 100% | 67% | 63% | 83% |
| **SIGN 157:** Risk reduction and management of delirium  | 94% | 97% | 65% | 81% | 73% | 58% | 67% |
| Management of delirium in older people  | 100% | 89% | 72% | 89% | 50% | 79% | 83% |

Domain 1: Scope and purpose

Domain 2: Stakeholder involvement

Domain 3: Rigour of development

Domain 4: Clarity of presentation

Domain 5: Applicability

Domain 6: Editorial independence

OA: overall assessment

# **Appendix 4: Table of excluded studies, with reasons**

|  |  |  |
| --- | --- | --- |
| **Author, date** | **Type of study** | **Reason for exclusion** |
| 1. Bak, 2019
 | SR\* | Wrong indication |
| 1. Belgamwar, 2005
 | SR | Wrong indication |
| 1. Burry, 2018
 | SR | Wrong intervention |
| 1. Burry, 2019
 | SR | Wrong intervention |
| 1. Dundar, 2016
 | SR | Wrong indication |
| 1. Fernández Sánchez, 2009
 | SR | Wrong indication |
| 1. Huf, 2009
 | SR | Wrong language |
| 1. Huf, 2016
 | SR | Wrong indication |
| 1. Lacasse, 2016
 | SR | Wrong intervention |
| 1. Maglione, 2011
 | SR | Wrong indication |
| 1. Mühlbauer, 2021
 | SR | Wrong patient population |
| 1. Nikooie, 2019
 | SR | Wrong intervention |
| 1. Paris, 2021
 | SR | Wrong indication |
| 1. Pelland, 2009
 | SR | Wrong language |
| 1. Seida, 2012
 | SR | Wrong patient population |
| 1. Shoptaw, 2009
 | SR | Wrong indication |
| 1. Tulloch, 2004
 | SR | Wrong indication |
| 1. Williamson, 2019
 | SR | Wrong indication |
| 1. Yildiz, 2003
 | SR | Wrong language |
| 1. Yildiz, Sachs 2003
 | SR | Wrong study design |
| 1. Yunusa, 2019
 | SR | Wrong indication |
| 1. Zaman, 2017
 | SR | Wrong indication |
| 1. Baldaҫara, 2011
 | RCT# | Wrong indication |
| 1. Battaglia, 2003
 | RCT | Wrong indication |
| 1. Battaglia, 2005
 | RCT | Wrong outcomes |
| 1. Beasley, 1996
 | RCT | Wrong indication |
| 1. Belgamwar, 2005
 | RCT | Wrong indication |
| 1. Bozzatello, 2017
 | RCT | Wrong patient population |
| 1. Breier, 2000
 | RCT | Awaiting classification |
| 1. Breier, 2001
 | RCT | Awaiting classification |
| 1. Breier, 2002
 | RCT | Wrong indication |
| 1. Chan, 2014
 | RCT | Wrong indication |
| 1. Clark, 2001
 | RCT | Wrong indication |
| 1. David, 2001
 | RCT | Awaiting classification |
| 1. Eli, 2005
 | RCT | Awaiting classification |
| 1. Faay, 2020
 | RCT | Wrong indication |
| 1. Fontaine, 2003
 | RCT | Wrong patient population |
| 1. Gareri, 2004
 | RCT | Wrong indication |
| 1. Hsu, 2010
 | RCT | Wrong indication |
| 1. Huf, 2009
 | RCT | Wrong intervention |
| 1. Huang, 2015
 | RCT | Wrong indication |
| 1. Hwang, 2012
 | RCT | Awaiting classification |
| 1. Jin, 2009
 | RCT | Awaiting classification |
| 1. Katagiri, 2013
 | RCT | Wrong indication |
| 1. Kinon, 2000
 | RCT | Wrong indication |
| 1. Kinon, 2001
 | RCT | Wrong outcomes |
| 1. Kinon, 2004
 | RCT | Wrong indication |
| 1. Kittipeerachon, 2016
 | RCT | Wrong intervention |
| 1. Kong, 2009
 | RCT | Awaiting classification |
| 1. Krakowski, 2014
 | RCT | Wrong indication |
| 1. Lindbord, 2003
 | RCT | Wrong outcomes |
| 1. Meehan, 2001
 | RCT | Awaiting classification |
| 1. Meehan, 2001 (1)
 | RCT | Awaiting classification |
| 1. Meehan, 2001 (2)
 | RCT | Awaiting classification |
| 1. Meehan, 2001 (3)
 | RCT | Wrong indication |
| 1. Meehan, 2002
 | RCT | Wrong indication |
| 1. Mintzer, 2002
 | RCT | Awaiting classification |
| 1. Ono, 2008
 | RCT | Awaiting classification |
| 1. Raveendran, 2007
 | RCT | Wrong indication |
| 1. Schneider, 2006
 | RCT | Wrong indication |
| 1. Smith, 2003
 | RCT | Awaiting classification |
| 1. Street, 2000
 | RCT | Wrong patient population |
| 1. Svestka, 2002
 | RCT | Awaiting classification |
| 1. Verhey, 2006
 | RCT | Wrong indication |
| 1. Villari, 2009
 | RCT | Wrong intervention |
| 1. Wright, 2001
 | RCT | Awaiting classification |
| 1. Wright, 2003
 | RCT | Wrong indication |
| 1. Hirsch, 2019
 | Narrative review | Wrong study design |
| 1. Houston, 2019
 | Narrative review | Wrong study design |
| 1. Wagstaff, 2005
 | Narrative review | Wrong study design |
| 1. Pascual, 2007
 | Observational study | Wrong study design |
| 1. Walther, 2014
 | Observational study | Wrong study design |
| 1. ACTRN12610000033044
 | Ongoing trial | Wrong indication |
| 1. NCT00316238
 | Ongoing trial | Wrong indication |
| 1. NCT00485810
 | Ongoing trial | Wrong indication |
| 1. NCT00485901
 | Ongoing trial | Wrong indication |
| 1. NCT011234082
 | Ongoing trial | Wrong indication |
| 1. NCT00649510
 | Ongoing trial | Wrong indication |
| 1. NCT00797277
 | Ongoing trial | Wrong indication |
| 1. NCT00833300, 2009
 | Registered trial | Registered trial, trial stopped for recruitment issues |
| 1. NCT00970281
 | Ongoing trial | Wrong indication |
| 1. Elsayem, 2010
 | Pilot study | Wrong study design |
| 1. Citrome, 2007
 | Quantitative review | Wrong study design  |
| 1. Srivastava, 2010
 | Summary of review | Wrong study design |
| 1. deAlmeida, 2017
 | Review of reviews | Wrong study design |
| 1. Jones, 2001
 | Summary of RCTs | Wrong study design |
| \*SR = systematic review, #RCT = randomized controlled trial  |  |

# **Appendix 5: Table of Ongoing Trials**

|  |  |  |  |
| --- | --- | --- | --- |
| **Citation** | **Study Design** | **Population (n)** | **Treatment** |
| Arak University of Medical Sciences. IRCT20141209020258N114, first registered 3 July 2019, recruiting. | RCT with parallel assignment | 50 | Patients randomised to haloperidol 2.5mg (max 40mg) intramuscular injection (IMI) every 6 hours or olanzapine 2.5 to 10mg (max 20mg) orally |
| Arak University of Medical Sciences. IRCT20200927048852N1, first registered 13 October, recruiting. | Phase III RCT with parallel assignment | 90 | Patients randomised to haloperidol 2.5mg per day for up to 10 days or olanzapine 2.5mg to 10mg per day for up to 10 days or quetiapine 12.5 to 75mg per day |
| HCA Hospice Care. NCT04750395, first registered 11 February 2021, ongoing | RCT with parallel assignment | 80 | Patients randomised to transmucosal haloperidol, two doses of 2.5mg every 24 hours with up to two breakthrough doses or transmucosal olanzapine, two doses of 5mg with up to two breakthrough doses |
| Tan Tock Seng Hospital. NCT04833023, first registered 6 April 2021. | RCT with parallel assignment | 72 | Patients randomised to haloperidol oral solution 1mg (max 6mg in 24 hours), 2 hourly until max reached with midazolam 2mg as rescue dose (2mg q2h prn) or olanzapine orodispersible tablet 2.5mg (max 15mg in 24 hours), 2 hourly until max reached with midazolam 2mg as rescue dose (2mg q2h prn) |